Clinical Rheumatology

, Volume 29, Issue 9, pp 957–964 | Cite as

Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis

  • Theodoros Dimitroulas
  • Georgios Giannakoulas
  • Klio Papadopoulou
  • Tilemahos Sfetsios
  • Haralambos Karvounis
  • Hariklia Dimitroula
  • Despina Parcharidou
  • Georgios Koliakos
  • Alexandros Garyfallos
  • Ioannis Styliadis
  • Loukas Settas
Original Article

Abstract

Early detection of pulmonary hypertension (PH) in patients with systemic sclerosis (SSc) is essential as it leads to substantial morbidity and mortality irrespective of its etiology. The aim of our study was to determine whether noninvasive biochemical and/or echocardiographic indices can predict the presence of PH in these patients. We prospectively studied 66 patients (mean age of 57.7 ± 12.1 years, 63 women) with SSc without clinical manifestations of heart failure. All patients underwent standard and tissue Doppler echocardiography. Plasma N-terminal pro-B type natriuretic peptide (NT-proBNP) and asymmetric dimethylarginine (ADMA) levels were also measured. In 24 (36%) patients, the diagnosis of PH was established by echocardiography (systolic pulmonary artery pressure value ≥40 mmHg). Left atrial (LA) volume, NT-proBNP, ADMA, ratio of early transmitral filling velocity to early diastolic velocity of the mitral annulus (mitral E/Em), and right ventricular myocardial performance index (MPI) were univariate predictors of PH. In multivariate analysis, NT-proBNP, LA volume, and right ventricular MPI were independent predictors of PH in SSc patients. LA volume and NT-proBNP may be useful noninvasive markers for the prediction of elevated pulmonary artery pressure in patients with SSc. These parameters should be considered when assessing this population for risk stratification and for identification of patients demanding further investigation and institution of specific therapy for the disease at the time when it is most likely to be effective.

Keywords

Left atrial volume N-terminal pro-brain natriuretic peptide Pulmonary hypertension Systemic sclerosis 

References

  1. 1.
    Fonseca C, Abraham D, Ponticos M (2009) Neuronal regulators and vascular dysfunction in Raynaud's phenomenon and systemic sclerosis. Curr Vasc Pharmacol 71:34–39CrossRefGoogle Scholar
  2. 2.
    Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A (2003) The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology 42:534–540CrossRefPubMedGoogle Scholar
  3. 3.
    Hachulla E, de Groote P, Gressin V, Sibilia J, Diot E, Carpentier P, Mouthon L, Hatron PY, Jego P, Allanore Y, Tiev KP, Agard C, Cosnes A, Cirstea D, Constans J, Farge D, Viallard JF, Harle JR, Patat F, Imbert B, Kahan A, Cabane J, Clerson P, Guillevin L, Humbert M, Itinér AIR-Sclérodermie Study Group (2009) The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum 60:1831–1839CrossRefPubMedGoogle Scholar
  4. 4.
    Dimitroulas T, Giannakoulas G, Karvounis H, Koliakos G, Sfetsios T, Dimitroula H, Settas L (2008) N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. Clin Rheumatol 27:655–658CrossRefPubMedGoogle Scholar
  5. 5.
    Simeoni S, Lippi G, Puccetti A, Montagnana M, Tinazzi E, Prati D, Corrocher R, Lunardi C (2008) N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatol Int 28:657–660CrossRefPubMedGoogle Scholar
  6. 6.
    Dimitroulas T, Giannakoulas G, Karvounis H, Dimitroula H, Settas L (2009) N-terminal pro-brain natriuretic peptide in systemic sclerosis related pulmonary arterial hypertension under bosentan treatment. Rheumatol Int 29:347–348CrossRefPubMedGoogle Scholar
  7. 7.
    Coral-Alvarado P, Quintana G, Garces MF, Cepeda LA, Caminos JE, Rondon F, Iglesias-Gamarra A, Restrepo JF (2009) Potential biomarkers for detecting pulmonary arterial hypertension in patients with systemic sclerosis. Rheumatol Int 29:1017–1024CrossRefPubMedGoogle Scholar
  8. 8.
    Dimitroulas T, Giannakoulas G, Sfetsios T, Karvounis H, Dimitroula H, Koliakos G, Settas L (2008) Asymmetrical dimethylarginine in systemic sclerosis related pulmonary arterial hypertension. Rheumatology 47:1682–1685CrossRefPubMedGoogle Scholar
  9. 9.
    Williams MH, Handler CE, Akram R, Smith CJ, Das C, Smee J, Nair D, Denton CP, Black CM, Coghlan JG (2006) Role of N-terminal brain natriuretic peptide (NT-proBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 27:1485–1494CrossRefPubMedGoogle Scholar
  10. 10.
    Dimitroulas T, Giannakoulas G, Karvounis H, Sfetsios T, Koliakos G, Parcharidis G, Settas L (2007) Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension. Int J Cardiol 121:135–137CrossRefPubMedGoogle Scholar
  11. 11.
    Giannoni A, Tani C, Clerico A, Passino C, Tavoni A, d'Ascanio A, Bombardieri S, Emdin M (2009) When the heart is burning: amino-terminal pro-brain natriuretic peptide as an early marker of cardiac involvement in active autoimmune rheumatic disease. Int J Cardiol (in press)Google Scholar
  12. 12.
    Dimitroulas T, Giannakoulas G, Papadopoulou C, Karvounis H, Dimitroula H, Koliakos G, Karamitsos T, Parcharidou D, Settas L (2010) Early detection of cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography: relationship with neurohormonal activation and endothelial dysfunction. J Rheumatol 37:993–999CrossRefPubMedGoogle Scholar
  13. 13.
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of the systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRefGoogle Scholar
  14. 14.
    Dooley A, Gao B, Bradley N, Abraham DJ, Black CM, Jacobs M, Bruckdorfer KR (2006) Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology 45:676–684CrossRefPubMedGoogle Scholar
  15. 15.
    American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 2:358–367Google Scholar
  16. 16.
    Ren JF, Kotler MN, DePace NL, Mintz GS, Kimbiris D, Kalman P, Ross J (1983) Two-dimensional echocardiographic determination of left atrial emptying volume: a noninvasive index in quantifying the degree of nonrheumatic mitral regurgitation. J Am Coll Cardiol 2:729–736CrossRefPubMedGoogle Scholar
  17. 17.
    Currie P, Seward J, Reeder G (1985) Continuous-wave Doppler echocardiographic assessment of severity of calcific aortic stenosis: a simultaneous Doppler-catheter correlative study in 100 adult patients. Circulation 71:1162–1169PubMedGoogle Scholar
  18. 18.
    Ommen S, Nishimura R, Hurrell D, Klarich KW (2000) Assessment of right atrial pressure with 2-dimensional and Doppler echocardiography: a simultaneous catheterization and echocardiographic study. Mayo Clin Proc 75:24–29CrossRefPubMedGoogle Scholar
  19. 19.
    Mukerjee D, St George D, Knight C, Davar J, Wells AU, Du Bois RM, Black CM, Coghlan JG (2004) Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology 43:461–466CrossRefPubMedGoogle Scholar
  20. 20.
    Tei C, Dujardin KS, Hodge DO, Bailey KR, McGoon MD, Tajik AJ, Seward SB (1996) Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr 9:838–847CrossRefPubMedGoogle Scholar
  21. 21.
    Pope JE, Lee P, Baron M, Dunne J, Smith D, Docherty PS, Bookman A, Abu-Hakima M (2005) Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. J Rheumatol 32:1273–1278PubMedGoogle Scholar
  22. 22.
    de Azevedo AB, Sampaio-Barros PD, Torres RM, Moreira C (2005) Prevalence of pulmonary hypertension in systemic sclerosis. Clin Exp Rheumatol 23:447–454PubMedGoogle Scholar
  23. 23.
    Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, Kahan A, Cabane J, Francès C, Launay D, Mouthon L, Allanore Y, Tiev KP, Clerson P, de Groote P, Humbert M (2005) Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 52:3792–3800CrossRefPubMedGoogle Scholar
  24. 24.
    Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, Black CM, Coghlan JG (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62:1088–1093CrossRefPubMedGoogle Scholar
  25. 25.
    Ciurzyński M, Bienias P, Lichodziejewska B, Kurnicka K, Szewczyk A, Glińska-Wielochowska M, Kurzyna M, Błaszczyk M, Liszewska-Pfejfer D, Pruszczyk P (2008) Non-invasive diagnostic and functional evaluation of cardiac involvement in patients with systemic sclerosis. Clin Rheumatol 27:991–997CrossRefPubMedGoogle Scholar
  26. 26.
    Mukerjee D, Yap LB, Holmes AM, Nair D, Ayrton P, Black CM, Coghlan JG (2003) Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 97:1230–1236CrossRefPubMedGoogle Scholar
  27. 27.
    Dimitroulas T, Giannakoulas G, Karvounis H, Gatzoulis M, Settas L (2010) Natriuretic peptides in systemic sclerosis-related pulmonary arterial hypertension. Semin Arthritis Rheum 39:478–484CrossRefGoogle Scholar
  28. 28.
    Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, Mouthon L, Guillevin L, Meyer O, Ekindjian OG, Weber S, Kahan A (2008) High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 58:284–291CrossRefPubMedGoogle Scholar
  29. 29.
    Triposkiadis F, Harbas C, Kelepeshis G, Sitafidis G, Skoularigis J, Demopoulos V, Tsilimingas N (2007) Left atrial remodeling in patients younger than 70 years with diastolic and systolic heart failure. J Am Soc Echocardiogr 20:177–185CrossRefPubMedGoogle Scholar
  30. 30.
    Maione S, Cuomo G, Giunta A, Tanturri de Horatio L, La Montagna G, Manguso F, Alagia I, Valentini G (2005) Echocardiographic alterations in systemic sclerosis: a longitudinal study. Semin Arthritis Rheum 34:721–727CrossRefPubMedGoogle Scholar
  31. 31.
    Meune C, Avouac J, Wahbi K, Cabanes L, Wipff J, Mouthon L, Guillevin L, Kahan A, Allanore Y (2008) Cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography during routine care: a controlled study of 100 consecutive patients. Arthritis Rheum 58:1803–1809CrossRefPubMedGoogle Scholar
  32. 32.
    Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L, Krishnan JA, Wigley F, Hassoun PM (2006) Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 54:3043–3050CrossRefPubMedGoogle Scholar
  33. 33.
    Tumminello G, Lancellotti P, Lempereur M, D'Orio V, Pierard LA (2007) Determinants of pulmonary artery hypertension at rest and during exercise in patients with heart failure. Eur Heart J 28:569–574CrossRefPubMedGoogle Scholar
  34. 34.
    Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB (2002) Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol 90:1284–1289CrossRefPubMedGoogle Scholar
  35. 35.
    Karayannis G, Kitsios G, Kotidis H, Triposkiadis F (2008) Left atrial remodelling contributes to the progression of asymptomatic left ventricular systolic dysfunction to chronic symptomatic heart failure. Heart Fail Rev 13:91–98CrossRefPubMedGoogle Scholar
  36. 36.
    Yeo TC, Dujardin KS, Tei C, Mahoney DW, McGoon MD, Seward JB (1998) Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 81:1157–1161CrossRefPubMedGoogle Scholar
  37. 37.
    Giunta A, Tirri E, Maione S, Cangianiello S, Mele A, De Luca A, Valentini G (2000) Right ventricular diastolic abnormalities in systemic sclerosis. Relation to left ventricular involvement and pulmonary hypertension. Ann Rheum Dis 59:94–98CrossRefPubMedGoogle Scholar
  38. 38.
    Vonk MC, Sander MH, van den Hoogen FH, van Riel PL, Verheugt FW, van Dijk AP (2007) Right ventricle Tei-index: a tool to increase the accuracy of non-invasive detection of pulmonary arterial hypertension in connective tissue diseases. Eur J Echocardiogr 8:317–321CrossRefPubMedGoogle Scholar
  39. 39.
    Wilson Tang WH, Tong W, Shrestha K, Wang Z, Levison BS, Delfraino B, Hu B, Troughton RW, Klein AL, Hazen SL (2008) Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. Eur Heart J 29:2506–2513CrossRefPubMedGoogle Scholar
  40. 40.
    Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66:940–944CrossRefPubMedGoogle Scholar
  41. 41.
    Tsapenko MV, Tsapenko AV, Comfere TB, Mour GK, Mankad SV, Gajic O (2008) Arterial pulmonary hypertension in noncardiac intensive care unit. Vasc Health Risk Manag 4:1043–1060PubMedGoogle Scholar
  42. 42.
    Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, Barst RJ, Ghofrani HA, Jing ZC, Opitz C, Seyfarth HJ, Halank M, McLaughlin V, Oudiz RJ, Ewert R, Wilkens H, Kluge S, Bremer HC, Baroke E, Rubin LJ (2006) Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 48:2546–2552CrossRefPubMedGoogle Scholar
  43. 43.
    Keysser G, Schwerdt C, Taege C (2008) Right-heart failure after right heart catheterization in a patient with scleroderma and suspected pulmonary hypertension. Rheumatol Int 28:1269–1271CrossRefPubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2010

Authors and Affiliations

  • Theodoros Dimitroulas
    • 1
  • Georgios Giannakoulas
    • 2
  • Klio Papadopoulou
    • 2
  • Tilemahos Sfetsios
    • 1
  • Haralambos Karvounis
    • 2
  • Hariklia Dimitroula
    • 2
  • Despina Parcharidou
    • 2
  • Georgios Koliakos
    • 3
  • Alexandros Garyfallos
    • 4
  • Ioannis Styliadis
    • 2
  • Loukas Settas
    • 1
  1. 1.First Department of Internal MedicineAHEPA University HospitalThessalonikiGreece
  2. 2.First Department of CardiologyAHEPA University HospitalThessalonikiGreece
  3. 3.Department of BiochemistryAristotle University of ThessalonikiThessalonikiGreece
  4. 4.Fourth Department of Internal MedicineHippokration General HospitalThessalonikiGreece

Personalised recommendations